Details

Autor(en) / Beteiligte

• Tanner, Rikki M., MPH
• Calhoun, David A., MD
• Bell, Emmy K., MD
• Bowling, C. Barrett, MD, MSPH
• Gutiérrez, Orlando M., MD, MMSc
• Irvin, Marguerite R., PhD
• Lackland, Daniel T., DrPH
• Oparil, Suzanne, MD
• McClellan, William, MD
• Warnock, David G., MD
• Muntner, Paul, PhD

Titel

Incident ESRD and Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study

Ist Teil von

• American journal of kidney diseases, 2014-05, Vol.63 (5), p.781-788

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Studies suggest that treatment-resistant hypertension is common and increasing in prevalence among US adults. Although hypertension is a risk factor for end-stage renal disease (ESRD), few data are available for the association between treatment-resistant hypertension and ESRD risk. Study Design Prospective cohort study. Setting & Participants We analyzed data from 9,974 REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study participants treated for hypertension without ESRD at baseline. Predictor Treatment-resistant hypertension was defined as uncontrolled blood pressure (BP) with concurrent use of 3 antihypertensive medication classes including a diuretic or use of 4 or more antihypertensive medication classes including a diuretic regardless of BP. Outcome Incident ESRD was identified by linkage of REGARDS Study participants with the US Renal Data System. Measurements During a baseline in-home study visit, BP was measured twice and classes of antihypertensive medication being taken were determined by pill bottle inspection. Results During a median follow-up of 6.4 years, there were 152 incident cases of ESRD (110 ESRD cases among 2,147 with treatment-resistant hypertension and 42 ESRD cases among 7,827 without treatment-resistant hypertension). The incidence of ESRD per 1,000 person-years for hypertensive participants with and without treatment-resistant hypertension was 8.86 (95% CI, 7.35-10.68) and 0.88 (95% CI, 0.65-1.19), respectively. After multivariable adjustment, the HR for ESRD comparing hypertensive participants with versus without treatment-resistant hypertension was 6.32 (95% CI, 4.30-9.30). Of participants who developed incident ESRD during follow-up, 72% had treatment-resistant hypertension at baseline. Limitations BP, estimated glomerular filtration rate, and albuminuria assessed at a single time. Conclusions Individuals with treatment-resistant hypertension are at increased risk for ESRD. Appropriate clinical management strategies are needed to treat treatment-resistant hypertension in order to preserve kidney function in this high-risk group.